StemSmart Delivers Positive Clinical Outcomes in Special Access Program
NeuroScientific Biotherapeutics Limited (ASX: NSB) announced a price-sensitive clinical update reporting successful outcomes from patients with fistulising Crohn’s disease treated with its StemSmart™ mesenchymal stem cell therapy under a Special Access Program. Four patients were treated in the initial cohort; three achieved a successful clinical response, and the remaining patient showed a partial response with ongoing improvement.
A clinical response was defined as either closure of at least half of fistula openings or a reduction of fistula discharge by at least 50 percent, as assessed by clinicians. These outcomes provide meaningful validation of the StemSmart™ platform in a real-world clinical setting. Importantly, data generated from this program will directly inform the design of planned later-phase clinical trials, which are expected to commence in the second half of 2026. The company also confirmed that Phase 2 preparation activities are progressing, including manufacturing, regulatory planning, and trial development. The announcement is price sensitive due to its implications for clinical progress and future development pathways.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions
StemSmart Delivers Positive Clinical Outcomes in Special Access Program
NeuroScientific Biotherapeutics Limited (ASX: NSB) announced a price-sensitive clinical update reporting successful outcomes from patients with fistulising Crohn’s disease treated with its StemSmart™ mesenchymal stem cell therapy under a Special Access Program. Four patients were treated in the initial cohort; three achieved a successful clinical response, and the remaining patient showed a partial response with ongoing improvement.
A clinical response was defined as either closure of at least half of fistula openings or a reduction of fistula discharge by at least 50 percent, as assessed by clinicians. These outcomes provide meaningful validation of the StemSmart™ platform in a real-world clinical setting. Importantly, data generated from this program will directly inform the design of planned later-phase clinical trials, which are expected to commence in the second half of 2026. The company also confirmed that Phase 2 preparation activities are progressing, including manufacturing, regulatory planning, and trial development. The announcement is price sensitive due to its implications for clinical progress and future development pathways.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au